NGS-Guided Precision Oncology in Breast Cancer and Gynecological Tumors—A Retrospective Molecular Tumor Board Analysis
Authors:
- Niklas GremkeNGNiklas Gremke
- Fiona R. RodepeterFRFiona R. Rodepeter
- Julia Teply-SzymanskiJTJulia Teply-Szymanski
- Sebastian GriewingSGSebastian Griewing
- Jelena BoekhoffJBJelena Boekhoff
- Alina StrohASAlina Stroh
- Thomas S. TarawnehTTThomas S. Tarawneh
- Jorge Riera-KnorrenschildJRJorge Riera-Knorrenschild
- Christina BalserCBChristina Balser
- Akira HattesohlAHAkira Hattesohl
- Martin MiddekeMMMartin Middeke
- Petra RossPRPetra Ross
Open Access
Abstract
Background: Precision oncology treatments are being applied more commonly in breast and gynecological oncology through the implementation of Molecular Tumor Boards (MTBs), but real-world clinical outcome data remain limited. Methods: A retrospective analysis was conducted in patients with breast cancer (BC) and gynecological malignancies referred to our center’s MTB from 2018 to 2023. The analysis covered patient characteristics, next-generation sequencing (NGS) results, MTB recommendations, therapy received, and clinical outcomes. Results: Sixty-three patients (77.8%) had metastatic disease, and forty-four patients (54.3%) had previously undergone three or more lines of systemic treatment. Personalized treatment recommendations were provided to 50 patients (63.3%), while 29 (36.7%) had no actionable target. Ultimately, 23 patients (29.1%) underwent molecular-matched treatment (MMT). Commonly altered genes in patients with pan-gyn tumors (BC and gynecological malignancies) included TP53 (n = 42/81, 51.9%), PIK3CA (n = 18/81, 22.2%), BRCA1/2 (n = 10/81, 12.3%), and ARID1A (n = 9/81, 11.1%). Patients treated with MMT showed significantly prolonged progression-free survival (median PFS 5.5 vs. 3.5 months, p = 0.0014). Of all patients who underwent molecular profiling, 13.6% experienced a major clinical benefit (PFSr ≥ 1.3 and PR/SD ≥ 6 months) through precision oncology. Conclusions: NGS-guided precision oncology demonstrated improved clinical outcomes in a subgroup of patients with gynecological and breast cancers.Keywords
Funding Information
- Stiftung P.E. Kempkes (01/2021, 03/2022 MR, 01/2023, AH 06-01)
- University Medical Center Giessen and Marburg (01/2021, 03/2022 MR, 01/2023, AH 06-01)
- Von Behring-Röntgen Stiftung (01/2021, 03/2022 MR, 01/2023, AH 06-01)
- Clinician Scientist program of the Philipps University of Marburg (01/2021, 03/2022 MR, 01/2023, AH 06-01)
- Carreras Leukemia foundation (01/2021, 03/2022 MR, 01/2023, AH 06-01)
- DFG, German Research Foundation (01/2021, 03/2022 MR, 01/2023, AH 06-01)
This publication has 69 references indexed in Scilit:
- Klinisch relevante molekularpathologische Diagnostik beim MammakarzinomDie Pathologie, 2023
- Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)Genetics in Medicine, 2022
- NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMUArchives of Gynecology and Obstetrics, 2020
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2020
- Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’European Journal of Cancer, 2020
- Variant classification in precision oncologyInternational Journal of Cancer, 2019
- Der prädiktive Wert der PD-L1-DiagnostikDer Pathologe, 2018
- A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast CancersCancer Cell, 2018
- Implementing Genome-Driven OncologyCell, 2017
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009